ArticleAmerican journal of translational research2025
Mechanism of PPARα agonist in alopecia areata.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the involvement and mechanisms of PPARα agonists in alopecia areata (AA).
methodsAA models were established using skin grafting, adoptive T-cell transfer, and TCR retrograde T-cell transfer methods. Relative PPARα expression levels in C3H/HeJ AA mice and AA patients were evaluated using qPCR and immunohistochemistry (IHC). Hair changes in mice following treatment were documented photographically, while immunofluorescence staining was employed to assess inflammatory factor dynamics in the skin. Additionally, ELISA and flow cytometry were used to analyze AA-related immune factors and cell populations in treated mice.
resultsPPARα agonists demonstrated protective effects in C3H/HeJ skin graft AA models and TCR transgenic AA mice, promoting early reversal of AA. They effectively inhibited T effector cell function and exerted immunomodulatory effects.
conclusionThe PPARα signaling pathway plays a key role in AA pathogenesis. PPARα agonists show therapeutic potential for AA as an inflammatory condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.